ARTICLE | Clinical News
Gazyvaro regulatory update
August 4, 2014 7:00 AM UTC
The European Commission approved Gazyvaro obinutuzumab from Roche in combination with chlorambucil as first-line treatment of chronic lymphocytic leukemia (CLL) in patients unsuitable for fludarabine-...